Deleting IGF-1 receptor from forebrain neurons confers neuroprotection during stroke and upregulates endocrine somatotropin

Journal of Cerebral Blood Flow and Metabolism

Volumn 37, Issue 2, 2017, Pages 396-412

  De Magalhaes Filho, C Daniel ^a,b   Kappeler, Laurent ^a,b   Dupont, Joëlle ^c   Solinc, Julien ^a   Villapol, Sonia ^a   Denis, Cécile ^a,b,d   Nosten Bertrand, Marika ^a,b,d   Billard, Jean Marie ^e   Blaise, Annick ^a,b   Tronche, François ^a,b,d   Giros, Bruno ^a,b,d,f   Charriaut Marlangue, Christiane ^a   Aïd, Saba ^a,b   Le Bouc, Yves ^a,b   Holzenberger, Martin ^a,b  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UMR85 PHYSIOLOGIE DE LA REPRODUCTION ET DES COMPORTEMENTS   (France)

^d Département de Biologie   (France)

^e CENTRE DE PSYCHIATRIE ET NEUROSCIENCES   (France)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

Cerebral edema; hypoxia ischemia; insulin like growth factor; neuroinflammation; neuroprotection

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN EDEMA; BRAIN ISCHEMIA; BRAIN NERVE CELL; CELL DAMAGE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; FOREBRAIN; GENE DELETION; GENOTYPE; GROWTH HORMONE RELEASE; HIPPOCAMPUS; INTRACELLULAR SIGNALING; MALE; MOUSE; NERVE CELL PLASTICITY; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SYNAPTIC POTENTIAL; SYNAPTIC TRANSMISSION; UPREGULATION; ANIMAL; C57BL MOUSE; GENETICS; KNOCKOUT MOUSE; METABOLISM; NERVE CELL; PATHOLOGY;

ANIMALS; FEMALE; GENE DELETION; GROWTH HORMONE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURONS; NEUROPROTECTION; PROSENCEPHALON; RECEPTOR, IGF TYPE 1; STROKE; UP-REGULATION;

EID: 85009904356     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1177/0271678X15626718     Document Type: Article

References (60)

1. Russo VC, Gluckman PD, Feldman EL, et al. The insulin-like growth factor system and its pleiotropic functions in brain. Endocr Rev 2005; 26: 916-943.
2. Aleman A and Torres-Aleman I. Circulating insulin-like growth factor I and cognitive function: neuromodulation throughout the lifespan. Prog Neurobiol 2009; 89: 256-265.
3. Dupont J and Holzenberger M. Biology of insulin-like growth factors in development. Birth Defects Res C 2003; 69: 257-271.
4. Desbois-Mouthon C, Wendum D, Cadoret A, et al. Hepatocyte proliferation during liver regeneration is impaired in mice with liver-specific IGF-1R knockout. FASEB J 2006; 20: 773-775.
5. Rowland KJ, Trivedi S, Lee D, et al. Loss of glucagon-like peptide-2-induced proliferation following intestinal epithelial insulin-like growth factor-1 receptor deletion. Gastroenterology 2011; 141: 2166-2175.
6. Nishijima T, Piriz J, Duflot S, et al. Neuronal activity drives localized blood-brain-barrier transport of serum insulin-like growth factor-I into the CNS. Neuron 2010; 67: 834-846.
7. Mitschelen M, Yan H, Farley JA, et al. Long-term deficiency of circulating and hippocampal insulin-like growth factor I induces depressive behavior in adult mice: a potential model of geriatric depression. Neuroscience 2011; 185: 50-60.
8. Fernandez AM and Torres-Aleman I. The many faces of insulin-like peptide signalling in the brain. Nat Rev Neurosci 2012; 13: 225-239.
9. Carro E, Trejo JL, Nunez A, et al. Brain repair and neuroprotection by serum insulin-like growth factor I. Mol Neurobiol 2003; 27: 153-162.
10. Trejo JL, Piriz J, Llorens-Martin MV, et al. Central actions of liver-derived insulin-like growth factor I underlying its pro-cognitive effects. Mol Psychiatry 2007; 12: 1118-1128.
11. O'Donnell SL, Frederick TJ, Krady JK, et al. IGF-I and microglia/macrophage proliferation in the ischemic mouse brain. Glia 2002; 39: 85-97.
12. Liu W, D'Ercole JA and Ye P. Blunting type 1 insulinlike growth factor receptor expression exacerbates neuronal apoptosis following hypoxic/ischemic injury. BMC Neurosci 2011; 12: 64.
13. Guan J, Bennet L, Gluckman PD, et al. Insulin-like growth factor-1 and post-ischemic brain injury. Prog Neurobiol 2003; 70: 443-462.
14. Zhu W, Fan Y, Hao Q, et al. Postischemic IGF-1 gene transfer promotes neurovascular regeneration after experimental stroke. J Cereb Blood Flow Metab 2009; 29: 1528-1537.
15. Sun C, Meng Q, Zhang L, et al. Glutamate attenuates IGF-1 receptor tyrosine phosphorylation in mouse brain: possible significance in ischemic brain damage. Neurosci Res 2012; 74: 290-297.
16. Chen DY, Stern SA, Garcia-Osta A, et al. A critical role for IGF-II in memory consolidation and enhancement. Nature 2011; 469: 491-497.
17. Krieger F, Elflein N, Saenger S, et al. Polyethylene glycol-coupled IGF1 delays motor function defects in a mouse model of spinal muscular atrophy with respiratory distress type 1. Brain 2014; 137: 1374-1393.
18. Torres-Aleman I. Targeting insulin-like growth factor-1 to treat Alzheimer's disease. Expert Opin Ther Targets 2007; 11: 1535-1542.
19. Cohen E, Paulsson JF, Blinder P, et al. Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell 2009; 139: 1157-1169.
20. Benarroch EE. Insulin-like growth factors in the brain and their potential clinical implications. Neurology 2012; 79: 2148-2153.
21. Endres M, Piriz J, Gertz K, et al. Serum insulin-like growth factor I and ischemic brain injury. Brain Res 2007; 1185: 328-335.
22. Yan H, Mitschelen M, Toth P, et al. Endothelin-1-induced focal cerebral ischemia in the growth hormone/ IGF-1 deficient Lewis Dwarf rat. J Gerontol A Biol Sci Med Sci 2014; 69: 1353-1362.
23. Ahamed K, Epaud R, Holzenberger M, et al. Deficiency in type 1 insulin-like growth factor receptor in mice protects against oxygen-induced lung injury. Respir Res 2005; 6: 31.
24. Cadoret A, Rey C, Wendum D, et al. IGF-1R contributes to stress-induced hepatocellular damage in experimental cholestasis. Am J Pathol 2009; 175: 627-635.
25. Gontier G, George C, Chaker Z, et al. Blocking IGF signaling in adult neurons alleviates Alzheimer's disease pathology through Ab clearance. J Neurosci 2015; 35: 11500-11513.
26. Holzenberger M, Dupont J, Ducos B, et al. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 2003; 421: 182-187.
27. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med 2011; 3: 70ra13.
28. Mantamadiotis T, Lemberger T, Bleckmann SC, et al. Disruption of CREB function in brain leads to neurode-generation. Nat Genet 2002; 31: 47-54.
29. Mao X, Fujiwara Y and Orkin SH. Improved reporter strain for monitoring Cre recombinase-mediated DNA excisions in mice. Proc Natl Acad Sci USA 1999; 96: 5037-5042.
30. Morice E, Billard JM, Denis C, et al. Parallel loss of hippocampal LTD and cognitive flexibility in a genetic model of hyperdopaminergia. Neuropsychopharmacology 2007; 32: 2108-2116.
31. Levine S. Anoxic-ischemic encephalopathy in rats. Am J Pathol 1960; 36: 1-17.
32. Vannucci SJ, Willing LB, Goto S, et al. Experimental stroke in the female diabetic, db/db, mouse. J Cereb Blood Flow Metab 2001; 21: 52-60.
33. Zhang L, Nair A, Krady K, et al. Estrogen stimulates microglia and brain recovery from hypoxia-ischemia in normoglycemic but not diabetic female mice. J Clin Invest 2004; 113: 85-95.
34. Xu J, Gontier G, Chaker Z, et al. Longevity effect of IGF-1R(+/-) mutation depends on genetic background-specific receptor activation. Aging Cell 2014; 13: 19-28.
35. Dikkes P, Jaffe DB, Guo WH, et al. IGF2 knockout mice are resistant to kainic acid-induced seizures and neurode-generation. Brain Res 2012; 17: 85-95.
36. Cohen E, Du D, Joyce D, et al. Temporal requirements of insulin/IGF-1 signaling for proteotoxicity protection. Aging Cell 2010; 9: 126-134.
37. Freude S, Hettich MM, Schumann C, et al. Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer's disease. FASEB J 2009; 23: 3315-3324.
38. Xie L, Sun F, Wang J, et al. mTOR signaling inhibition modulates macrophage/microglia-mediated neuroinflam-mation and secondary injury via regulatory T cells after focal ischemia. J Immunol 2014; 192: 6009-6019.
39. Subramaniam S, Zirrgiebel U, von Bohlen und Halbach O, et al. ERK activation promotes neuronal degeneration predominantly through plasma membrane damage and independently of caspase-3. J Cell Biol 2004; 165: 357-369.
40. Singh K, Maity P, Krug L, et al. Superoxide anion radicals induce IGF-1 resistance through concomitant activation of PTP1B and PTEN. EMBO Mol Med 2015; 7: 59-77.
41. Garcia-Galloway E, Arango C, Pons S, et al. Glutamate excitotoxicity attenuates insulin-like growth factor-I pro-survival signaling. Mol Cell Neurosci 2003; 24: 1027-1037.
42. Wiera G, Szczot M, Wojtowicz T, et al. Impact of matrix metalloproteinase-9 overexpression on synaptic excitatory transmission and its plasticity in rat CA3-CA1 hippocampal pathway. J Physiol Pharmacol 2015; 66: 309-315.
43. Vnencak M, Paul MH, Hick M, et al. Deletion of the amyloid precursor-like protein 1 (APLP1) enhances excitatory synaptic transmission, reduces network inhibition but does not impair synaptic plasticity in the mouse dentate gyrus. J Comp Neurol 2015; 523: 1717-1729.
44. Chaker Z, Aid S, Berry H, et al. Suppression of IGF-I signals in neural stem cells enhances neurogenesis and olfactory function during aging. Aging Cell 2015; 14: 847-856.
45. Choi SH, Aid S and Bosetti F. The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research. Trends Pharmacol Sci 2009; 30: 174-181.
46. Fernandez AM, Fernandez S, Carrero P, et al. Calcineurin in reactive astrocytes plays a key role in the interplay between proinflammatory and anti-inflammatory signals. J Neurosci 2007; 27: 8745-8756.
47. Genis L, Davila D, Fernandez S, et al. Astrocytes require insulin-like growth factor I to protect neurons against oxidative injury. F1000Research 2014; 3: 28.
48. Swanson RA, Ying W and Kauppinen TM. Astrocyte influences on ischemic neuronal death. Curr Mol Med 2004; 4: 193-205.
49. Block ML, Zecca L and Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007; 8: 57-69.
50. Zhu Z, Zhang Q, Yu Z, et al. Inhibiting cell cycle progression reduces reactive astrogliosis initiated by scratch injury in vitro and by cerebral ischemia in vivo. Glia 2007; 55: 546-558.
51. Frago LM, Paneda C, Dickson SL, et al. Growth hormone (GH) and GH-releasing peptide-6 increase brain insulin-like growth factor-I expression and activate intra-cellular signaling pathways involved in neuroprotection. Endocrinology 2002; 143: 4113-4122.
52. Lopez-Lopez C, LeRoith D and Torres-Aleman I. Insulin-like growth factor I is required for vessel remodeling in the adult brain. Proc Natl Acad Sci U S A 2004; 101: 9833-9838.
53. Wang CX and Shuaib A. Critical role of microvascula-ture basal lamina in ischemic brain injury. Prog Neurobiol 2007; 83: 140-148.
54. Balthasar N, Mery PF, Magoulas CB, et al. Growth hormone-releasing hormone (GHRH) neurons in GHRH-enhanced green fluorescent protein transgenic mice: a ventral hypothalamic network. Endocrinology 2003; 144: 2728-2740.
55. Staiger JF and Wouterlood FG. Efferent projections from the lateral septal nucleus to the anterior hypothalamus in the rat: a study combining Phaseolus vulgaris-leucoagglu-tinin tracing with vasopressin immunocytochemistry. Cell Tissue Res 1990; 261: 17-23.
56. Kloting N, Koch L, Wunderlich T, et al. Autocrine IGF-1 action in adipocytes controls systemic IGF-1 concentrations and growth. Diabetes 2008; 57: 2074-2082.
57. Moloney AM, Griffin RJ, Timmons S, et al. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 2010; 31: 224-243.
58. Bomfim TR, Forny-Germano L, Sathler LB, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Abeta oligomers. J Clin Invest 2012; 122: 1339-1353.
59. Talbot K, Wang HY, Kazi H, et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012; 122: 1316-1338.
60. Caccamo A, Branca C, Talboom JS, et al. Reducing ribo-somal protein S6 kinase 1 expression improves spatial memory and synaptic plasticity in a mouse model of Alzheimer's disease. J Neurosci 2015; 35: 14042-14056.